AR122899A1 - Combinación de vacunas - Google Patents
Combinación de vacunasInfo
- Publication number
- AR122899A1 AR122899A1 ARP210101904A ARP210101904A AR122899A1 AR 122899 A1 AR122899 A1 AR 122899A1 AR P210101904 A ARP210101904 A AR P210101904A AR P210101904 A ARP210101904 A AR P210101904A AR 122899 A1 AR122899 A1 AR 122899A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccines
- cov
- sars
- antigens
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2010425.3A GB2596820A (en) | 2020-07-07 | 2020-07-07 | Combination vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122899A1 true AR122899A1 (es) | 2022-10-12 |
Family
ID=72050416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101904A AR122899A1 (es) | 2020-07-07 | 2021-07-07 | Combinación de vacunas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230256085A1 (enExample) |
| EP (1) | EP4178612A1 (enExample) |
| JP (1) | JP2023533772A (enExample) |
| KR (1) | KR20230049084A (enExample) |
| CN (1) | CN117957016A (enExample) |
| AR (1) | AR122899A1 (enExample) |
| AU (1) | AU2021303789A1 (enExample) |
| BR (1) | BR112023000323A2 (enExample) |
| CA (1) | CA3184878A1 (enExample) |
| CO (1) | CO2023001072A2 (enExample) |
| GB (1) | GB2596820A (enExample) |
| IL (1) | IL299735A (enExample) |
| MX (1) | MX2023000411A (enExample) |
| TW (1) | TW202207979A (enExample) |
| WO (1) | WO2022009121A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| US20230416309A1 (en) * | 2020-10-23 | 2023-12-28 | Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji | Fusion protein and application thereof |
| CN113293145B (zh) * | 2021-02-01 | 2022-08-26 | 上海青赛生物科技有限公司 | 一种麻疹病毒活载体新冠疫苗 |
| EP4322994A1 (en) * | 2021-04-14 | 2024-02-21 | ModernaTX, Inc. | Influenza-coronavirus combination vaccines |
| JP2024516309A (ja) * | 2021-05-05 | 2024-04-12 | ノババックス，インコーポレイテッド | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 |
| CN113462700B (zh) * | 2021-05-07 | 2023-06-09 | 杨光华 | SARS-CoV-2线性DNA疫苗 |
| CN114717251B (zh) * | 2021-08-24 | 2023-03-24 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗 |
| WO2023047419A1 (en) * | 2021-09-24 | 2023-03-30 | Bharat Biotech International Limited | A vaccine for coronavirus and influenza virus, and method for preparation thereof |
| CN113755644B (zh) * | 2021-09-24 | 2024-05-03 | 中国科学院武汉病毒研究所 | 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN114891817A (zh) * | 2022-04-15 | 2022-08-12 | 华南理工大学 | 一种多聚肽及其制备方法与应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024174012A1 (pt) * | 2023-02-24 | 2024-08-29 | Instituto Butantan | Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal |
| CN115992101B (zh) * | 2023-03-22 | 2023-07-28 | 深圳市卫光生物制品股份有限公司 | 一种流感病毒裂解疫苗原液的制备方法 |
| CN116350769B (zh) * | 2023-03-31 | 2024-07-19 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用 |
| CN116327910B (zh) * | 2023-03-31 | 2024-05-03 | 北京吉诺卫生物科技有限公司 | 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用 |
| EP4710936A4 (en) * | 2023-05-10 | 2026-08-12 | Univ Hokkaido Nat Univ Corp | COMBINED VACCINE FOR THE PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS |
| CN118141906B (zh) * | 2024-02-22 | 2025-08-22 | 安徽智飞龙科马生物制药有限公司 | 一种新冠流感联合疫苗及其制备方法 |
| WO2026123991A1 (zh) * | 2024-12-12 | 2026-06-18 | 中国人民解放军军事科学院军事医学研究院 | 一种含有脂肪酸化修饰的SpyCatcher蛋白的免疫组合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| CN1775287A (zh) * | 2004-11-16 | 2006-05-24 | 北京科兴生物制品有限公司 | 一种sars流感二价联合疫苗及其制备工艺 |
| GB0822001D0 (en) * | 2008-12-02 | 2009-01-07 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2012104820A1 (en) * | 2011-02-04 | 2012-08-09 | Pfizer Inc. | Compositions for canine respiratory disease complex |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| US20130236494A1 (en) * | 2012-03-06 | 2013-09-12 | Crucell Holland B.V. | Vaccination against influenza |
| CN107961371B (zh) * | 2017-04-19 | 2020-08-11 | 武汉博沃生物科技有限公司 | 季节流感-rsv联合疫苗及其制备方法和应用 |
| CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
| CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
| CN111218458B (zh) * | 2020-02-27 | 2020-11-20 | 珠海丽凡达生物技术有限公司 | 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法 |
-
2020
- 2020-07-07 GB GB2010425.3A patent/GB2596820A/en not_active Withdrawn
-
2021
- 2021-07-07 MX MX2023000411A patent/MX2023000411A/es unknown
- 2021-07-07 TW TW110125037A patent/TW202207979A/zh unknown
- 2021-07-07 EP EP21740222.1A patent/EP4178612A1/en active Pending
- 2021-07-07 WO PCT/IB2021/056102 patent/WO2022009121A1/en not_active Ceased
- 2021-07-07 CN CN202180054553.3A patent/CN117957016A/zh active Pending
- 2021-07-07 CA CA3184878A patent/CA3184878A1/en active Pending
- 2021-07-07 AU AU2021303789A patent/AU2021303789A1/en active Pending
- 2021-07-07 AR ARP210101904A patent/AR122899A1/es unknown
- 2021-07-07 IL IL299735A patent/IL299735A/en unknown
- 2021-07-07 JP JP2023501632A patent/JP2023533772A/ja active Pending
- 2021-07-07 KR KR1020237003756A patent/KR20230049084A/ko active Pending
- 2021-07-07 US US18/015,025 patent/US20230256085A1/en active Pending
- 2021-07-07 BR BR112023000323A patent/BR112023000323A2/pt unknown
-
2023
- 2023-01-31 CO CONC2023/0001072A patent/CO2023001072A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL299735A (en) | 2023-03-01 |
| CO2023001072A2 (es) | 2023-06-20 |
| KR20230049084A (ko) | 2023-04-12 |
| WO2022009121A1 (en) | 2022-01-13 |
| TW202207979A (zh) | 2022-03-01 |
| US20230256085A1 (en) | 2023-08-17 |
| GB2596820A (en) | 2022-01-12 |
| MX2023000411A (es) | 2023-04-10 |
| AU2021303789A1 (en) | 2023-02-16 |
| EP4178612A1 (en) | 2023-05-17 |
| GB202010425D0 (en) | 2020-08-19 |
| JP2023533772A (ja) | 2023-08-04 |
| CN117957016A (zh) | 2024-04-30 |
| BR112023000323A2 (pt) | 2023-01-31 |
| CA3184878A1 (en) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023001072A2 (es) | Vacuna combinada de sars-cov-2 e influenza | |
| AR121361A1 (es) | Vacuna | |
| CO2024006742A2 (es) | Compuestos terapéuticos para la infección por el virus del vih | |
| ECSP17077930A (es) | Métodos y kits para tratar la depresión | |
| CO2019001379A2 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih . | |
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| CO2021006308A2 (es) | Proteínas f de prefusión del vrs estabilizadas | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| CL2019003805A1 (es) | Composiciones inmunógenas de senecavirus a y métodos de éstas. | |
| BR112017001310A2 (pt) | coronavírus | |
| MX2018003198A (es) | Moduladores de proteínas básicas de la hepatitis b. | |
| UY32457A (es) | Vacuna del virus del dengue inactivado | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| CL2018002692A1 (es) | Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961) | |
| MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| BR112022016893A2 (pt) | Vacina contra a infecção do vírus da peste suína africana | |
| MX383330B (es) | Particula tipo virus de flavivirus. | |
| CL2023000699A1 (es) | Tratamientos de angioedema | |
| MX2017009309A (es) | Derivados de indol mono o disustituido como inhibidores de la replicacion del virus del dengue. | |
| CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
| CL2007002710A1 (es) | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. | |
| BR112023026164A2 (pt) | Bacteriófagos contra enterococci resistentes à vancomicina | |
| BR112022009421A2 (pt) | Regimes de dosagem para vacinas |